Transitions in relabeling personalized medicine as precision medicine, precision health, or wellness genomics reflect shifting the locus of responsibility for health from individuals to clinicians and in shifting focus from genetic risk to genetic enhancement.
AMA J Ethics. 2018;20(9):E881-890. doi:
10.1001/amajethics.2018.881.
Physicians, committees, and guardians all make decisions for unrepresented patients in the US. This article considers a “tiered” approach as an alternative.
AMA J Ethics. 2019;21(7):E587-593. doi:
10.1001/amajethics.2019.587.
When patients are unable to express their wishes and do not have surrogates or advance directives, which and whose values should inform decision making for them? We discuss ethical complexities of caring for unrepresented patients.